Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation. Under the terms of the agreement, Evotec will apply its integrated drug discovery platform including medicinal chemistry, computational chemistry and in vitro pharmacology to optimize hit compounds identified and selected from the Evotec compound library collection through a recent successful high-throughput screening campaign executed at Evotec.